Volumina Medical, developing novel biomaterials for dermatology and plastic surgery, closed its Series A round by existing and new investors. It will enable the medtech company to advance clinical program with its lead product Adipearl after having obtained promising First in Human Data, and ultimately achieve market approval in key international markets.
Adipearl is an innovative injectable dermal filler enabling the regeneration of soft tissues. The product addresses the need of millions of patients that require the reconstruction or regeneration of tissues after surgery, disease or for aesthetic purposes. The product is currently being used in clinical trials by world-renowned key opinion leaders in Europe.
Volumina Medical will use the funding gather additional and valuable clinical data to bring Adipearl to the market and ultimately help millions of patients that currently lack natural and durable solutions for improving their health and wellbeing.
“I will never forget the intensity of the smiles on face of the first patients that were treated with Adipearl. Together with this funding round it is providing us a lot of confidence and an extremely high energy to continue to develop Volumina Medical and offer our solution to millions of patients”, said Amélie Béduer, CEO and CO-Founder of Volumina.
Innovative approach leads to stable results
Each year, millions of patients suffer from the loss of soft tissue volume, for example: muscles, adipose tissues, glandular tissues. Soft tissue loss may occur from trauma, tumor ablation, or simply aging processes. The loss of soft tissue is frequently permanent and causes disfiguring tissue depression, which can not only have an impact cosmetically, but also functionally.
Volumina Medical based at Biopôle in the Lausanne area offers a potential alternative to current treatment methods through the development of a regenerative medicine approach where a biomaterial scaffold facilitates tissue regeneration in the defect area, enabling minimally invasive repair of 3D volumes in a single injection session.
Graph: Volumina Medical
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines